Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

Immune checkpoint inhibitor (ICI) immunotherapy improved the survival of head and neck squamous cell carcinoma (HNSCC) patients. However, more than 80% of the patients are still resistant to this therapy. To test whether the efficacy of ICI therapy can be improved by vaccine-induced immunity, we inv...

Full description

Bibliographic Details
Main Authors: Ramireddy Bommireddy, Luis E. Munoz, Anita Kumari, Lei Huang, Yijian Fan, Lenore Monterroza, Christopher D. Pack, Sampath Ramachandiran, Shaker J.C. Reddy, Janet Kim, Zhuo G. Chen, Nabil F. Saba, Dong M. Shin, Periasamy Selvaraj
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Vaccines
Subjects:
cancer
vaccine
adjuvants
IL-12
TMVs
MOC1
Online Access:https://www.mdpi.com/2076-393X/8/2/182

Internet

https://www.mdpi.com/2076-393X/8/2/182

Similar Items